Sector News

Stryker Acquires the Assets of CHG Hospital Beds, Inc.

January 5, 2015
Life sciences
Stryker Corporation announced today the asset acquisition of privately-held CHG Hospital Beds, Inc. (“CHG”) in an all cash transaction. CHG, headquartered in London, Ontario, Canada, sells innovative hospital beds that serve markets across Canada, the United States and the United Kingdom.
 
Founded in 2003, CHG designs, manufactures and markets a series of low-height hospital beds and related accessories. CHG’s beds allow a patient’s feet to sit flat on the floor while he/she is sitting at the edge of the bed. The low-height design helps reduce the risk of patient falls that are related to entering and exiting hospital beds. Among CHG’s innovative offerings is the recently launched Spirit One bed which is an expandable low-height bariatric bed for the acute care segment.
 
“The acquisition of CHG aligns with Stryker’s commitment to offering products that enhance the quality of care for both patients and healthcare professionals; in this case, aiding in the prevention of patient related injuries resulting from a fall from a hospital bed,” said Timothy J. Scannell, Group President, MedSurg and Neurotechnology. “This acquisition will bolster Stryker Medical’s bed offerings and allow us to offer additional solutions to our customers.”
 
The transaction is expected to be neutral to Stryker’s 2015 earnings per share excluding acquisition, integration-related and intangible amortization charges and accretive thereafter.
 
Source: Stryker

comments closed

Related News

October 10, 2021

Nutraceutical giants’ partnerships inject life back into industry at Vitafoods

Life sciences

Some of industry’s biggest players are joining forces to bring cost-effective yet scientifically backed offerings to the nutraceuticals market. Co-creation is reinvigorating supplement innovation, pairing together companies’ diverse expertise, sales networks and clinical trial investments.

October 10, 2021

Pilot launch complete: GlaxoSmithKline’s malaria shot scores WHO backing for wider rollout in Africa

Life sciences

GlaxoSmithKline has spent many years developing and testing its world-first malaria vaccine, but even after a positive recommendation from European regulators in 2015, the shot still isn’t widely deployed. That’s set to change with the World Health Organization’s (WHO’s) blessing for the vaccine.

October 10, 2021

Henrietta Lacks’ estate sues Thermo Fisher for continued sale of HeLa cells without family consent

Life sciences

A sample of Henrietta Lacks’ tissue was taken from her cervix without her consent while she was undergoing cancer treatment at Johns Hopkins Hospital in 1951. Her cells have subsequently been used to develop the polio vaccine, HPV vaccines and gene-mapping techniques and continue to be sold for research purposes by Thermo Fisher Scientific.

Send this to a friend